Back

Checkpoint nano-degrader to transiently promote efferocytosis in acute myocardial infarction

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Risk stratification in acute coronary syndromes (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Jinfeng Gao

Zhongshan Hospital, Shanghai (China)

6 More presentations in this session

Presentation thumbnail
GDF-15 is associated with worse ischemic and bleeding outcomes in the acute phase and during follow-up in patients with acute coronary syndrome: insights from the TRACER trial
Doctor C. Wassberg (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
The specificity of cardiac troponin elevations for myocardial infarction declines with age
Doctor R. Hasselbalch (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Growth differentiation factor-15 is associated with myocardial infarction and death at 30 and 90 days in ED patients with suspected acute coronary syndrome
Doctor B. Allen (Gainesville, US)
Abstract Slides Video
Presentation thumbnail
Effect of symptoms recognition in patients with recurrent acute myocardial infarction: from KRAMI-RCC
Doctor K. Kim (Jinju, KR)
Abstract Slides Video
Presentation thumbnail
Effect of a restrictive vs. liberal blood transfusion strategy among patients with acute myocardial infarction and anemia according to heart failure. A subgroup analysis of the REALITY trial.
Professor G. Ducrocq (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification in acute coronary syndromes (1)

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Pro-efferocytic heart-homing polymeric nanoparticles alleviate acute myocardial infraction injury
thumbnail
Congress Presentation
Glycopolymer P-SF attenuates myocardial ischemia-reperfusion injury by modulating macrophage PANoptosis
thumbnail
Congress Presentation
Combined administration of atorvastatin and mesenchymal stem cells synergizes to attenuate inflammation and promote efferocytosis in atherosclerotic mice

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources